Condition: Buruli Ulcer · Sponsor: Barwon Health
The goal of this interventional clinical trial is to demonstrate the complete BU lesion healing rate by 52 weeks after treatment initiation, without relapse and/or curative intent excision surgery, after 10-28 days of telacebec (T) treatment. Males and females age 18 and older will be included. • Participants will attend visits every 2 weeks during treatment and thereafter every 2 weeks until week 24 Thereafter they will be followed by visits at weeks 30, 40, and 52. From week 10 to week 52, if the lesion has healed, follow-up visits may be remote.
This description comes directly from the study's public registry record.
Bree Sarah · +61 (03) 4215 3035 · BREE.SARAH@barwonhealth.org.au
Kate Ellis · +61 (03) 4215 2878 · KATHRYN.ELLIS@barwonhealth.org.au
Always discuss trial participation with your own doctor first.
| Barwon Health | Geelong, Victoria, Australia | Recruiting |
| Royal Melbourne Hospital | Melbourne, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06481163